These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22233588)

  • 1. Vandetanib (Caprelsa) for medullary thyroid cancer.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
    [No Abstract]   [Full Text] [Related]  

  • 2. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
    Keating GM; Lyseng-Williamson KA; Frampton JE
    BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG; Haddad RI
    Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
    Duplomb S; Benoit A; Mechtouff-Cimarelli L; Cho TH; Derbel O; Peix JL; de la Fouchardière C
    J Clin Oncol; 2012 Jan; 30(2):e21-3. PubMed ID: 22162581
    [No Abstract]   [Full Text] [Related]  

  • 6. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib: in medullary thyroid cancer.
    Frampton JE
    Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
    Jalalat SZ; Cohen PR
    Int J Dermatol; 2015 Jun; 54(6):e213-6. PubMed ID: 25040327
    [No Abstract]   [Full Text] [Related]  

  • 9. Vandetanib: first global approval.
    Commander H; Whiteside G; Perry C
    Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN; Banaszynski ME; Kolesar JM
    Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer.
    Xian TC; Yang MY; Zhang XL; Wang J; Luo Y
    Horm Metab Res; 2024 Sep; 56(9):649-653. PubMed ID: 38278145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
    Thornton K; Kim G; Maher VE; Chattopadhyay S; Tang S; Moon YJ; Song P; Marathe A; Balakrishnan S; Zhu H; Garnett C; Liu Q; Booth B; Gehrke B; Dorsam R; Verbois L; Ghosh D; Wilson W; Duan J; Sarker H; Miksinski SP; Skarupa L; Ibrahim A; Justice R; Murgo A; Pazdur R
    Clin Cancer Res; 2012 Jul; 18(14):3722-30. PubMed ID: 22665903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib: too dangerous in medullary thyroid cancer.
    Prescrire Int; 2012 Oct; 21(131):233. PubMed ID: 23185843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
    Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
    Solomon B; Rischin D
    J Clin Oncol; 2012 Jan; 30(2):119-21. PubMed ID: 22025155
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinase inhibitors for advanced medullary thyroid carcinoma.
    Schlumberger M; Massicotte MH; Nascimento CL; Chougnet C; Baudin E; Leboulleux S
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):125-9. PubMed ID: 22584717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.